Immunisation is the process through which a person becomes protected against an infectious disease by developing immunity, most commonly through vaccination but sometimes through naturally acquired infection or the passive transfer of antibodies. The term is therefore broader than vaccination: vaccination refers specifically to administering a vaccine, whereas immunisation concerns the acquisition of protective immune status resulting from an immunological process.
Active immunisation occurs when a person's own immune system is stimulated to generate an adaptive response and immunological memory, typically after vaccination or infection. Passive immunisation occurs when preformed antibodies are transferred to an individual, such as maternal antibodies crossing the placenta or antibodies administered as an immunoglobulin preparation. Active immunity generally has greater potential for persistence because immune memory can be generated, whereas passive immunity is temporary because transferred antibodies gradually decline and do not normally establish the recipient's own antigen-specific memory.
Active immunisation involves coordinated innate and adaptive immune mechanisms. Following antigen exposure, antigen-presenting cells initiate processes that activate antigen-specific lymphocytes, including B cells and T cells. B cells can produce antibodies directed against pathogen components, while T cells can provide helper functions or, in appropriate circumstances, directly eliminate infected cells. Memory B and T cells can persist after the initial response and respond more rapidly upon subsequent exposure.
The quality and duration of immunisation depend on the antigen, vaccine platform or infectious exposure, dose, route, age, immune status, previous antigen exposure and characteristics of the pathogen. Some immune responses decline over time, but immunological memory may persist even when circulating antibody concentrations fall. Consequently, measurable antibody concentration and biological protection are related but are not always identical concepts, and different diseases require different correlates of protection.
The terminology surrounding immunisation reflects its historical development within infectious-disease medicine and public health. Immunity derives from the Latin immunis, associated with being exempt or protected from an obligation, and the modern biological meaning developed as scientists established that prior exposure could confer resistance to particular diseases. The development of vaccination provided a practical method for inducing active immunity without requiring the disease itself, while advances in immunology subsequently clarified the roles of antibodies, lymphocytes and memory cells.
The discovery and use of antitoxins and immunoglobulins established important forms of passive immunisation, particularly for situations in which immediate protection is needed. Modern immunisation practice therefore encompasses a range of strategies rather than a single technology, and the distinction between active and passive immunity is fundamental to understanding why some interventions provide rapid but temporary protection while others take time to develop but can generate longer-lasting immune memory.
Immunisation can be assessed at several levels. At the individual level, clinicians may consider whether a person has received recommended vaccines, has evidence of previous infection, possesses relevant antibody responses, or requires additional protection because of age, occupation, travel or medical circumstances. At the programme level, immunisation coverage measures uptake within defined populations and schedules, while surveillance assesses disease incidence and identifies groups in which susceptibility remains high.
Serological testing can measure antibodies for selected diseases, but the presence or absence of a particular antibody does not universally provide a complete measure of immunity. Some vaccines require multiple doses because a single exposure does not produce the desired magnitude or durability of protection. Conversely, not every vaccine requires indefinite boosting, because recommendations depend on the characteristics of the vaccine, pathogen, population and evidence concerning duration of protection.
Passive immunisation has distinctive applications because it can provide antibodies immediately. Maternal antibodies can provide infants with temporary protection against certain infections, although their concentration and duration vary and maternal antibodies can sometimes interfere with responses to particular vaccines. Therapeutic or prophylactic antibody preparations can be used in selected circumstances involving exposure to infectious agents, particularly when rapid protection is needed or when active immunisation cannot provide sufficiently prompt protection. Passive products can include polyclonal immunoglobulins or specific antibody preparations.
Their protection generally diminishes as the administered antibodies are metabolised, and they ordinarily do not create the same durable immunological memory associated with active immunisation. The distinction is clinically important because active and passive approaches have different timing, duration, mechanisms, indications and limitations, and in some situations they can be used in combination according to established protocols.
Immunisation is closely related to herd immunity, but the terms describe different levels of protection. Immunisation generally concerns the protected individual or the process that creates individual immunity, whereas herd immunity describes a population-level reduction in transmission that results when a sufficiently large proportion of a population is immune or otherwise resistant. Immunisation is also not synonymous with complete sterilising immunity. A person can have useful immunity that substantially reduces severe disease without being completely protected against infection or transmission.
Immune protection can vary by pathogen, disease outcome and time since exposure or vaccination. These distinctions prevent a common misconception that an immunised person necessarily cannot carry or transmit a pathogen. The epidemiological consequences of immunisation depend on the relationship between individual immune responses and the pathogen's transmission characteristics.
Immunisation programmes are shaped by demographic structure, disease epidemiology, healthcare access and public-health policy. Infants, children, adolescents, adults, older people, pregnant individuals, healthcare workers, travellers and people with particular occupational or medical exposures can have different immunisation needs. Programme design must consider when susceptibility begins, how long protection lasts, whether a disease is severe in particular age groups and whether vaccination at one age affects later immune responses.
Catch-up programmes can be used to provide missed doses, while targeted interventions may address populations with lower coverage or increased exposure. Record systems, reminder mechanisms, healthcare-provider recommendations and accessible vaccination services can improve completion of schedules. Immunisation policy therefore combines immunological science with population management, logistics and communication rather than treating immunity as an isolated biological property.
The ultimate public-health significance of immunisation lies in reducing the burden of infectious disease and changing patterns of transmission and susceptibility. Successful immunisation can reduce cases, complications, hospitalisations and deaths, and sustained high levels of protection can sometimes interrupt transmission sufficiently to produce population-level benefits. However, immunity is not static: antibody concentrations can decline, immune responses can differ between individuals, and pathogen characteristics can change.
Programme effectiveness can consequently be influenced by coverage gaps, access inequalities, vaccine characteristics, waning protection and pathogen evolution. Immunisation should therefore be understood as a dynamic interaction between individual immune biology and population epidemiology. Accurate use of the term is especially important when distinguishing the administration of a vaccine, the resulting immune response, the temporary protection supplied by antibodies, and the broader population consequences of widespread immunity.
